Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II

Inclusion Criteria: * age \>18 years; * all patients with a clinical indication to Percutaneous Coronary Intervention (PCI) (stable coronary artery disease or acute coronary syndromes); * native coronary artery lesion in a vessel with diameter \>2.0 mm and ≦3.5 mm at visual estimation; * maximum lesion length: 50 mm. * informed consent to participate in the study. Exclusion Criteria: * patients with known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, prasugrel, ticagrelor, sirolimus or contrast media, which cannot be adequately pre-medicated; * patients participating in another clinical study; * subject is a woman who is pregnant or nursing (pregnancy test, either urine or blood test must be performed within 7 days prior to the index procedure in woman of child-bearing potential, and must not commit to initiating a pregnancy for 12 weeks after implantation, using effective contraception); * creatinine clearance \<30 ml/min; * left ventricular ejection fraction \<30%; * life expectancy \<12 months; * ST-elevation myocardial infarction in the previous 48 hours; * visible thrombus at lesion site; * culprit lesion stenosis \>99% and/or Thrombolysis In Myocardial Infarction (TIMI) flow \<2; * target lesion/vessel with any of the following characteristics: * concomitant PCI at the same vessel with any device (vessels are considered: left anterior descending, circumflex or right coronary artery); * pre-dilatation of the target lesion not…